The FDA has granted full approval to Mounjaro (tirzepatide), Eli Lilly’s once-weekly injectable twincretin agonist, for the treatment of type 2 diabetes mellitus on May 13. This pivotal regulatory milestone significantly enhances the drug’s commercial prospects by allowing for wider physician prescribing and insurancer coverage, strengthening Eli Lilly’s competitive position against market peers.